<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1031">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147727</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-I-108</org_study_id>
    <nct_id>NCT05147727</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects</brief_title>
  <official_title>A Single-center, Open-label, Fixed-sequence Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of Famitinib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, fixed-sequence, drug-drug interaction study to evaluate the effects of&#xD;
      fluconazole on the pharmacokinetics and safety of famitinib in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Fluconazole and famitinib interaction</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for famitinib</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to time t (AUC0-t,) for famitinib</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinity (AUC0-∞.) for famitinib (if applicable)</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) for famitinib</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination half-life (t1/2) for famitinib</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F) for famitinib</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for famitinib</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for famitinib metabolite SHR116637</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for famitinib metabolite SHR116637</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t, for famitinib metabolite SHR116637</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞. for famitinib metabolite SHR116637(if applicable)</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for famitinib metabolite SHR116637</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)</measure>
    <time_frame>Day 1 to Day 25</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Fluconazole and Famitinib interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole、Famitinib</intervention_name>
    <description>Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15</description>
    <arm_group_label>Fluconazole and Famitinib interaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. With my consent and informed consent, I am willing and able to complete the study in&#xD;
             accordance with the requirements of the experimental protocol;&#xD;
&#xD;
          2. Healthy male or female aged 18-45 years (including threshold) on the date of signing&#xD;
             the informed consent form;&#xD;
&#xD;
          3. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) in the&#xD;
             range of 19.0-26.0 kg / m2 (including the critical value);&#xD;
&#xD;
          4. Physical examination, vital signs, laboratory measurements (blood routine, blood&#xD;
             biochemistry, urine routine test, coagulation function, etc.), 12-lead ECG, abdominal&#xD;
             B-ultrasound, chest X-ray, etc. are normal or abnormal, but the researcher has no&#xD;
             clinical significance according to NCI CTCAE 5.0 standard;&#xD;
&#xD;
          5. Fertile subjects had no family planning and had to take acceptable contraceptive&#xD;
             measures and no plans to donate eggs and sperm within 3 months from the date of&#xD;
             signing informed consent to the last medication; the serum pregnancy test of fertile&#xD;
             women within 24 hours before the first administration of the study drug should be&#xD;
             negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have previously suffered from primary diseases of important organs,&#xD;
             including but not limited to neuropsychiatric, cardiovascular, digestive tract,&#xD;
             respiratory system, urinary, endocrine, blood, immune and other diseases, which are&#xD;
             judged by the researchers to be unsuitable for the trial;&#xD;
&#xD;
          2. Subjects who have received any previous operation affecting gastrointestinal&#xD;
             absorption;&#xD;
&#xD;
          3. Subjects who had received any surgery within 6 months before screening, or planned to&#xD;
             undergo surgery during the study period;&#xD;
&#xD;
          4. Those who lost blood or donated more than 400 ml or received blood transfusion within&#xD;
             3 months before screening;&#xD;
&#xD;
          5. HBsAg positive, HCVAb positive, HIV antibody positive, syphilis antibody positive;&#xD;
&#xD;
          6. History of drug use in the past 5 years or drug abuse, or drug screening positive;&#xD;
&#xD;
          7. Smoking and alcohol addict and unable to stop smoking during the test period; those&#xD;
             with positive alcohol screening; those with positive nicotine screening;&#xD;
&#xD;
          8. Subjects who have swallowing resistance or obstacle that will affect the drug&#xD;
             absorption;&#xD;
&#xD;
          9. Allergic constitution, including severe drug allergy or drug allergy history; known&#xD;
             allergy to fluconazole and famitinib or its excipients;&#xD;
&#xD;
         10. Those who have participated in other clinical trials and taken the study drug within 3&#xD;
             months before taking the study drug for the first time;&#xD;
&#xD;
         11. Inducers or inhibitors of CYP3A4 were taken within 4 weeks before the first&#xD;
             administration of study drug;&#xD;
&#xD;
         12. Taking any prescription drug, over-the-counter drug, traditional Chinese medicine or&#xD;
             food supplement within 2 weeks before taking the study drug for the first time;&#xD;
&#xD;
         13. Ingestion of grapefruit containing products, fruit juice, food or beverage containing&#xD;
             methylxanthine or alcohol within 48 hours before taking the study drug for the first&#xD;
             time; taking strenuous exercise; or having other factors affecting the absorption,&#xD;
             distribution, metabolism and excretion of drugs;&#xD;
&#xD;
         14. Lactating women;&#xD;
&#xD;
         15. The researchers considered that the subjects had any other factors that were not&#xD;
             suitable for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kai Shen</last_name>
    <phone>13511062039</phone>
    <email>kai.shen@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen Jing</last_name>
    <phone>17721286191</phone>
    <email>wen.jing@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

